Paratek Pharmaceuticals Inc  

(Public, NASDAQ:PRTK)   Watch this stock  
Find more results for NASDAQ:TSPT
-0.25 (-2.03%)
After Hours: 12.05 0.00 (0.00%)
Oct 21, 5:08PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.95 - 12.35
52 week 11.90 - 23.86
Open 12.20
Vol / Avg. 96,322.00/104,136.00
Mkt cap 273.78M
P/E     -
Div/yield     -
EPS -6.00
Shares 22.63M
Beta 1.47
Inst. own 86%
Nov 10, 2016
Q3 2016 Paratek Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 7, 2016
Paratek Pharmaceuticals Inc at Robert W Baird Global Healthcare Conference
Aug 4, 2016
Q2 2016 Paratek Pharmaceuticals Inc Earnings Release
Aug 4, 2016
Q2 2016 Paratek Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -85.87% -55.38%
Return on average equity -135.27% -72.14%
Employees 41 -
CDP Score - -


75 Park Plz Ste 4
BOSTON, MA 02116-3934
United States - Map
+1-617-8076600 (Phone)
+1-617-2750039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Paratek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek's antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company's sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company's other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class.

Officers and directors

Michael F. Bigham CPA Chairman of the Board, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Evan Loh M.D. President, Chief Medical Officer, Director
Age: 56
Bio & Compensation  - Reuters
Douglas W. Pagan Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
William M. Haskel Senior Vice President, General Counsel, Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Regina D. Paglia Senior Vice President - Human Resources
Bio & Compensation  - Reuters
Rajesh Padmanabhan Vice President - Information Technology
Bio & Compensation  - Reuters
Stephen Villano M.D. Vice President - Clinical and Medical Affairs
Bio & Compensation  - Reuters
Adam Woodrow Vice President and Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Timothy R. Franson M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Richard J. Lim Independent Director
Age: 43
Bio & Compensation  - Reuters